GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Stimulatory effect of ghrelin on isolated porcine somatotropes.
Glavaski-Joksimovic. Aleksandra A; Jeftinija. Ksenija K; Scanes. Colin G CG; Anderson. Lloyd L LL; Jeftinija. Srdija S
Key Findings
- Ghrelin dose‑dependently increases intracellular Ca2+ in porcine somatotropes, a signal that drives GH secretion.
- The increase is reduced by a GHS‑R antagonist ((D‑Lys(3))-GHRP‑6), confirming receptor‑mediated action.
- Calcium influx requires L‑type calcium channels and sodium channels; blocking these (e.g., with nifedipine) blunts the effect.
- Both adenylyl cyclase‑cAMP and phospholipase C‑IP3 pathways contribute to the calcium response.
- Synthetic GHS compounds (e.g., L‑585) produce the same calcium response as ghrelin, and they compete for the same receptor.
Practical Outcomes
- For biohackers using GHRP‑6, the data support that its GH‑boosting effect works through calcium entry, so adequate dietary calcium and avoiding calcium‑channel blockers may enhance results. The findings also warn that substances that block the ghrelin receptor or calcium channels could diminish GHRP‑6 efficacy. While the study is in pig cells, the mechanisms are likely similar in humans, offering a mechanistic rationale for current dosing protocols rather than a new dosing breakthrough.
Summary
The study shows that ghrelin (the natural hormone that GHRP‑6 mimics) makes growth‑hormone‑producing cells raise their internal calcium levels, which is a key trigger for GH release. This calcium rise depends on L‑type calcium channels, sodium channels, and signaling pathways that involve cAMP and PLC. Blocking the ghrelin receptor with a GHRP‑6‑derived antagonist stops the calcium increase, confirming the receptor’s role.
Abstract
Research on the mechanism for growth hormone secretagogue (GHS) induction of growth hormone secretion led to the discovery of the GHS receptor (GHS-R) and later to ghrelin, an endogenous ligand for GHS-R. The ability of ghrelin to induce an increase in the intracellular Ca(2+) concentration - [Ca(2+)](i) - in somatotropes was examined in dispersed porcine pituitary cells using a calcium imaging system. Somatotropes were functionally identified by application of human growth hormone releasing hormone. Ghrelin increased the [Ca(2+)](i) in a dose-dependent manner in 98% of the cells that responded to human growth hormone releasing hormone. In the presence of (D-Lys(3))-GHRP-6, a specific receptor antagonist of GHS-R, the increase in [Ca(2+)](i) evoked by ghrelin was decreased. Pretreatment of cultures with somatostatin or neuropeptide Y reduced the ghrelin-induced increase of [Ca(2+)](i). The stimulatory effect of ghrelin on somatotropes was greatly attenuated in low-calcium saline and blocked by nifedipine, an L-type calcium channel blocker, suggesting involvement of calcium channels. In a zero Na(+) solution, the stimulatory effect of ghrelin on somatotropes was decreased, suggesting that besides calcium channels, sodium channels are also involved in ghrelin-induced calcium transients. Either SQ-22536, an adenylyl cyclase inhibitor, or U73122, a phospholipase C inhibitor, decreased the stimulatory effects of ghrelin on [Ca(2+)](i) transiently, indicating the involvement of adenylyl cyclase-cyclic adenosine monophosphate and phospholipase C inositol 1,4,5-trisphosphate pathways. The nonpeptidyl GHS, L-692,585 (L-585), induced changes in [Ca(2+)](i) similar to those observed with ghrelin. Application of L-585 after ghrelin did not have additive effects on [Ca(2+)](i). Preapplication of L-585 blocked the stimulatory effect of ghrelin on somatotropes. Simultaneous application of ghrelin and L-585 did not cause an additive increase in [Ca(2+)](i). Our results suggest that the actions of ghrelin and synthetic GHS closely parallel each other, in a manner that is consistent with an increase of hormone secretion.
Study Information
pubmed
2003
2003-06-01T00:00:00.000Z
10.1159/000071309
55
42